Spliceor
The startup has developed a gene-therapy platform that targets aggressive cancers, specifically liver and pancreatic cancer, using a common therapeutic mechanism. This platform provides a curative treatment option for patients whose cancers are resistant to existing therapies, improving their overall health outcomes.
- Biotechnology
Updated 7 months ago
Funding
Raised to date
$690KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup has developed a gene-therapy platform that targets aggressive cancers, specifically liver and pancreatic cancer, using a common therapeutic mechanism. This platform provides a curative treatment option for patients whose cancers are resistant to existing therapies, improving their overall health outcomes.